Serious ARs (%)
24 (n=52)
Discontinuation due to ARs (%)
9 (n=20)
Common reasons for discontinuation (≥1%)
Pneumonitis (2%), blurred vision (1%), and peripheral neuropathy (1%)
Adverse REACTIONS in ≥10% of patients who received ELAHERE in MIRASOL1
The median duration of ELAHERE treatment was 5 months (range: 0.69 to 27.4)1
Adverse reaction
ELAHERE
(n=218)
Standard chemotherapy*
(n=207)
*Chemotherapy: paclitaxel, pegylated liposomal doxorubicin (PLD), topotecan.1
†Abdominal pain includes abdominal pain, abdominal pain upper, abdominal pain lower, and abdominal discomfort.1
‡Blurred vision includes vision blurred, vitreous floaters, visual acuity reduced, diplopia, accommodation disorder, and visual impairment.1
§Keratopathy includes corneal disorder, corneal epithelial microcysts, keratitis, keratopathy, corneal deposits, punctate keratitis, and corneal opacity.1
¶Dry eye includes dry eye and lacrimation increased.1
#Cataract includes cataract and cataract nuclear.1
**Peripheral neuropathy includes neuropathy peripheral, peripheral sensory neuropathy, peripheral motor neuropathy, paresthesia, hypoesthesia, polyneuropathy, neurotoxicity, and peripheral sensorimotor neuropathy.1
††Musculoskeletal pain includes back pain, myalgia, neck pain, arthralgia, musculoskeletal pain, noncardiac chest pain, bone pain, pain in extremity, musculoskeletal stiffness, musculoskeletal chest pain, and musculoskeletal discomfort.1
‡‡Pneumonitis includes pneumonitis, interstitial lung disease, respiratory failure, and organizing pneumonia.1
Laboratory abnormalities
Select laboratory abnormalities ≥10% for all grades in patients who received ELAHERE in MIRASOL1
Laboratory abnormality
ELAHERE
(n=218)
Standard chemotherapy
(n=207)
*The denominator used to calculate the rate varied from 63 to 214 (ELAHERE) and from 63 to 194 (IC chemotherapy) based on the number of patients with a baseline value and at least 1 posttreatment value.1
ALT=alanine aminotransferase; AST=aspartate aminotransferase; IC=investigator's choice.
Adverse reactions seen in MIRASOL
ELAHERE (n=218)1,2
Serious ARs (%)
24 (n=52)
Discontinuation due to ARs (%)
9 (n=20)
Common reasons for discontinuation (≥1%)
Pneumonitis (2%), blurred vision (1%), and peripheral neuropathy (1%)
The most common (≥2%) serious ARs with ELAHERE were intestinal obstruction (5%), abdominal pain (3%), and pleural effusion (3%). Fatal ARs occurred in 3% of patients and included intestinal obstruction, dyspnea in the setting of subileus, neutropenic sepsis, cardiopulmonary failure, respiratory failure, ischemic stroke, and pulmonary embolus1
![]()
Dosage delays of ELAHERE due to an AR occurred in 54% of patients treated with ELAHERE. ARs that required dosage delays in ≥3% of patients included1:
![]()
Dose reductions of ELAHERE due to an AR occurred in 34% of patients. ARs that required dose reductions in ≥3% of patients included1:
Clinically relevant ARs that occurred in <10% of patients who received ELAHERE included infusion-related reactions/hypersensitivity (8%)1
The median duration of ELAHERE treatment was 5 months (range: 0.69 to 27.4)1
AR=adverse reaction.
Additional adverse reactions of interest2,3
Adverse reactions reported in MIRASOL, in addition to safety data from the ELAHERE Prescribing Information
This analysis was not powered to demonstrate a difference in adverse reactions between ELAHERE and traditional chemotherapy.
General
Alopecia2,3
99% of patients did not have a reported hair loss with ELAHERE vs 86% of patients who did not have a reported hair loss with traditional chemotherapy
Gastrointestinal
Stomatitis2,3
3% of patients treated with ELAHERE experienced stomatitis vs 11% with standard chemotherapy
Hematologic
Anemia2,3
10% of patients treated with ELAHERE had anemia vs 34% with standard chemotherapy
Thrombocytopenia2,3
7% of patients treated with ELAHERE had thrombocytopenia vs 16% with standard chemotherapy
Neutropenia2,3
11% of patients treated with ELAHERE had neutropenia vs 29% with standard chemotherapy
Adverse reactions reported above were for all grades; ELAHERE (n=218), standard chemotherapy (n=207).2,3
OCULAR ADVERSE REACTIONS SEEN AND MANAGED ACROSS CLINICAL TRIALS1,2*
Ocular adverse reactions were mostly Grade 1 or 21,2
59% of patients treated with ELAHERE had an ocular adverse reaction; 11% of patients experienced Grade 3 ocular adverse reactions, 0.3% experienced Grade 4 reactions1
Nearly all ocular adverse reactions resolved to Grade 0 or 12
Of the patients treated with ELAHERE who had an ocular adverse reaction, 53% had complete resolution and 38% had partial improvement at last follow-up1†
1% of patients discontinued ELAHERE due to ocular adverse reactions1
Median time to onset of the first ocular adverse reaction was 5.1 weeks (range: 0.1 to 68.6)1
Ocular adverse reactions seen in MIRASOL2,4
56% (n=122) of patients treated with ELAHERE experienced an ocular adverse reaction vs 9% of patients receiving standard chemotherapy.
This analysis was not powered to demonstrate a difference in adverse reactions between ELAHERE and traditional chemotherapy.
NO NEW SAFETY SIGNALS IDENTIFIED IN THE LONGER-TERM FOLLOW-UP (MEDIAN 30.5 MONTHS)5
Updated safety by treatment cohort in MIRASOL6
Adverse reaction
ELAHERE
(n=218)
Standard chemotherapy*
(n=207)
*Grade 3 events not applicable for alopecia.6
Long-term safety adverse reactions are preferred terms and not grouped terms.6
Additional data from the ELAHERE Prescribing Information include1:
No inference can be drawn from this data set. Follow-up analysis is exploratory and data are descriptive in nature.
Updated safety overview in MIRASOL5
Adverse reaction, n (%)
ELAHERE (n=218)
Standard chemotherapy (n=207)
Any TEAR
211 (97)
194 (94)
Grade ≥3 TEAR
97 (44)
113 (55)
Serious TEARs
55 (25)
69 (33)
Treatment-related serious ARs
21 (10)
16 (8)
Dose reduction due to TEARs
77 (35)
50 (24)
Dose delays/holds due to TEARs
122 (56)
112 (54)
Discontinuations due to TEARs
25 (11)
31 (15)
Deaths on study drug or within 30 days of last dose
9 (4)
11 (5)
TEAR=treatment-emergent adverse reaction.
Long-term safety adverse reactions are preferred terms and not grouped terms.6
No inference can be drawn from this data set. Follow-up analysis is exploratory and data are descriptive in nature.
Resources for treatment
From eye care to access and reimbursement, information is available to support your patients and your practice.
How dose modifications can help
Dose modifications can help manage adverse reactions and keep patients on treatment.
IMPORTANT SAFETY INFORMATION AND INDICATION
WARNING: OCULAR TOXICITY
WARNINGS and PRECAUTIONS
Ocular Disorders
ELAHERE can cause severe ocular adverse reactions, including visual impairment, keratopathy (corneal disorders), dry eye, photophobia, eye pain, and uveitis.
Ocular adverse reactions occurred in 59% of patients with ovarian cancer treated with ELAHERE. Eleven percent (11%) of patients experienced Grade 3 ocular adverse reactions, including blurred vision, keratopathy (corneal disorders), dry eye, cataract, photophobia, and eye pain; two patients (0.3%) experienced Grade 4 events (keratopathy and cataract). The most common (≥5%) ocular adverse reactions were blurred vision (48%), keratopathy (36%), dry eye (27%), cataract (16%), photophobia (14%), and eye pain (10%).
The median time to onset for first ocular adverse reaction was 5.1 weeks (range: 0.1 to 68.6). Of the patients who experienced ocular events, 53% had complete resolution; 38% had partial improvement (defined as a decrease in severity by one or more grades from the worst grade at last follow up). Ocular adverse reactions led to permanent discontinuation of ELAHERE in 1% of patients.
Premedication and use of lubricating and ophthalmic topical steroid eye drops during treatment with ELAHERE are recommended. Advise patients to avoid use of contact lenses during treatment with ELAHERE unless directed by a healthcare provider.
Refer patients to an eye care professional for an ophthalmic exam including visual acuity and slit lamp exam prior to treatment initiation, every other cycle for the first 8 cycles, and as clinically indicated. Promptly refer patients to an eye care professional for any new or worsening ocular signs and symptoms.
Monitor for ocular toxicity and withhold, reduce, or permanently discontinue ELAHERE based on severity and persistence of ocular adverse reactions.
Pneumonitis
Severe, life-threatening, or fatal interstitial lung disease (ILD), including pneumonitis, can occur in patients treated with ELAHERE.
Pneumonitis occurred in 10% of patients treated with ELAHERE, including 1% with Grade 3 events and 1 patient (0.1%) with a Grade 4 event. One patient (0.1%) died due to respiratory failure in the setting of pneumonitis and lung metastases. One patient (0.1%) died due to respiratory failure of unknown etiology. Pneumonitis led to permanent discontinuation of ELAHERE in 3% of patients.
Monitor patients for pulmonary signs and symptoms of pneumonitis, which may include hypoxia, cough, dyspnea, or interstitial infiltrates on radiologic exams. Infectious, neoplastic, and other causes for such symptoms should be excluded through appropriate investigations. Withhold ELAHERE for patients who develop persistent or recurrent Grade 2 pneumonitis until symptoms resolve to ≤ Grade 1 and consider dose reduction. Permanently discontinue ELAHERE in all patients with Grade 3 or 4 pneumonitis. Patients who are asymptomatic may continue dosing of ELAHERE with close monitoring.
Peripheral Neuropathy (PN)
Peripheral neuropathy occurred in 36% of patients with ovarian cancer treated with ELAHERE across clinical trials; 3% of patients experienced Grade 3 peripheral neuropathy. Peripheral neuropathy adverse reactions included peripheral neuropathy (20%), peripheral sensory neuropathy (9%), paraesthesia (6%), neurotoxicity (3%), hypoaesthesia (1%), peripheral motor neuropathy (0.9%), polyneuropathy (0.3%), and peripheral sensorimotor neuropathy (0.1%). Monitor patients for signs and symptoms of neuropathy, such as paresthesia, tingling or a burning sensation, neuropathic pain, muscle weakness, or dysesthesia. For patients experiencing new or worsening PN, withhold dosage, dose reduce, or permanently discontinue ELAHERE based on the severity of PN.
Embryo-Fetal Toxicity
Based on its mechanism of action, ELAHERE can cause embryo-fetal harm when administered to a pregnant woman because it contains a genotoxic compound (DM4) and affects actively dividing cells.
Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with ELAHERE and for 7 months after the last dose.
ADVERSE REACTIONS
The most common (≥20 %) adverse reactions, including lab abnormalities, were increased aspartate aminotransferase, fatigue, increased alanine aminotransferase, blurred vision, nausea, increased alkaline phosphatase, diarrhea, abdominal pain, keratopathy, peripheral neuropathy, musculoskeletal pain, decreased lymphocytes, decreased platelets, decreased magnesium, decreased hemoglobin, dry eye, constipation, decreased leukocytes, vomiting, decreased albumin, decreased appetite, and decreased neutrophils.
DRUG INTERACTIONS
DM4 is a CYP3A4 substrate. Closely monitor patients for adverse reactions with ELAHERE when used concomitantly with strong CYP3A4 inhibitors.
USE IN SPECIAL POPULATIONS
Lactation
Advise women not to breastfeed during treatment with ELAHERE and for 1 month after the last dose.
Hepatic Impairment
Avoid use of ELAHERE in patients with moderate or severe hepatic impairment (total bilirubin >1.5 ULN).
INDICATION
ELAHERE is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based on an FDA-approved test.
US-EPROC-260280
Please see full Prescribing Information, including BOXED WARNING.
ULN=upper limit of normal.
References